PharmaDesign and Daiichi Conclude Licensing Agreement

PharmaDesign announced on June 8 that it has concluded a non-exclusive licensing agreement with Daiichi Pharmaceutical for Admensa Interactive, a suite of predictive drug absorption, distribution, metabolism and excretion (ADME) models and compound prioritization tools developed and provided by UK company Inpharmatica. Daiichi Pharmaceutical will be the first Japanese company to deploy Admensa Interactive, which helps the company reduce time and costs for drug development.

()a href="http://www.japancorp.net/Article.Asp?Art_ID=10274" target="_blank">Japan Corporate News Network